April 21, 2020
1 min read

Novartis acquires Amblyotech

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Novartis has acquired Ambylotech’s outstanding shares and will develop its digital technology for the treatment of amblyopia, according to a press release.

Active gaming and passive video technologies paired with 3D glasses are used to train eyes to work together to view a full image. This approach has resulted in vision improvements in children and adults faster than standard of care treatment in early clinical trials, the release said.

“We believe Novartis is best positioned to maximize the opportunity for our amblyopia treatment to reach and help patients who suffer from this condition,” Joseph Koziak, CEO of Amblyotech, said in the release. “The Amblyotech technology has the potential to be a first-in-class product for patients with this debilitating condition.”

Novartis plans to continue product development with the Research Institute of the McGill University Health Centre and Ubisoft Entertainment.